Business UpdateMay 6, 2026, 08:03 AM
Aktis Oncology CEO to Present at BofA Securities Health Care Conference
AI Summary
Aktis Oncology announced that its President and CEO, Matthew Roden, Ph.D., will present at the BofA Securities Health Care Conference on May 13, 2026. The presentation will be webcast live and an archived replay will be available for 90 days. Aktis Oncology is a clinical-stage company developing targeted radiopharmaceuticals, with lead programs AKY-1189 and AKY-2519 in its pipeline, and a collaboration with Eli Lilly and Company.
Key Highlights
- Aktis Oncology CEO Matthew Roden to present at BofA Securities Health Care Conference.
- Presentation scheduled for Wednesday, May 13, 2026, at 10:00 a.m. PT.
- A live webcast will be available via the Investors section of Aktis Oncology's website.
- An archived replay will be available for approximately 90 days post-conference.
- Aktis Oncology is a clinical-stage company focused on targeted radiopharmaceuticals.
- Company's lead program, AKY-1189, targets Nectin-4 for multiple tumor types.
- Second clinical-stage program, AKY-2519, targets B7-H3 expressing tumors.
- Aktis has a discovery collaboration with Eli Lilly and Company.
Price Impact
More from AKTS